Earlier presentation and application of curative treatments in hepatocellular carcinoma

Susanna V. Ulahannan, Austin G. Duffy, Timothy S. McNeel, Jonathan K. Kish, Lois A. Dickie, Osama E. Rahma, Katherine A. McGlynn, Tim F. Greten, Sean F. Altekruse – 4 July 2014 – The purpose of the study was to assess the use of curative therapies for hepatocellular carcinoma (HCC) in the population. HCC treatment patterns were examined in Surveillance, Epidemiology, and End Results (SEER) 18 registries (28% of U.S.).

Antagonistic interaction between Wnt and Notch activity modulates the regenerative capacity of a zebrafish fibrotic liver model

Mianbo Huang, Angela Chang, Minna Choi, David Zhou, Frank A. Anania, Chong Hyun Shin – 4 July 2014 – In chronic liver failure patients with sustained fibrosis, excessive accumulation of extracellular matrix proteins substantially dampens the regenerative capacity of the hepatocytes, resulting in poor prognosis and high mortality. Currently, the mechanisms and the strategies of inducing endogenous cellular sources such as hepatic progenitor cells (HPCs) to regenerate hepatocytes in various contexts of fibrogenic stimuli remain elusive.

Excess mortality on the liver transplant waiting list: Unintended policy consequences and model for End‐Stage Liver Disease (MELD) inflation

Patrick Grant Northup, Nicolas Michael Intagliata, Neeral Lalit Shah, Shawn Joseph Pelletier, Carl Lansing Berg, Curtis Kent Argo – 4 July 2014 – The Model for End‐Stage Liver Disease (MELD) allocation system for liver transplantation provides “exceptions” for diseases such as hepatocellular carcinoma (HCC). It was the aim of this study to assess equipoise between exception candidates and nonexception candidates on the waiting list and to assess if the exception system contributes to steadily increasing regional MELD at transplant.

Cost‐effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C

Emmanuel A. Tsochatzis, Catriona Crossan, Louise Longworth, Kurinchi Gurusamy, Manolo Rodriguez‐Peralvarez, Konstantinos Mantzoukis, Julia O'Brien, Evangelos Thalassinos, Vassilios Papastergiou, Anna Noel‐Storr, Brian Davidson, Andrew K. Burroughs – 4 July 2014 – The cost‐effectiveness of noninvasive tests (NITs) as alternatives to liver biopsy is unknown. We compared the cost‐effectiveness of using NITs to inform treatment decisions in adult patients with chronic hepatitis C (CHC).

Subscribe to